QVT Financial’s Iovance Biotherapeutics IOVA Stock Holding History

QVT Financial’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.82M	Hold	678,564	–	–	0.17%	41
2026 Q1	$2.38M	Hold	678,564	–	–	0.17%	44
2025 Q4	$1.85M	Hold	678,564	–	–	0.16%	33
2025 Q3	$1.47M	Hold	678,564	–	–	0.1%	33
2025 Q2	$1.17M	Hold	678,564	–	–	0.1%	38
2025 Q1	$2.26M	Hold	678,564	–	–	0.21%	28
2024 Q4	$5.02M	Hold	678,564	–	–	0.45%	23
2024 Q3	$6.37M	Hold	678,564	–	–	0.55%	20
2024 Q2	$5.44M	Hold	678,564	–	–	0.51%	19
2024 Q1	$10.1M	Hold	678,564	–	–	0.85%	18
2023 Q4	$5.52M	Hold	678,564	–	–	0.31%	21
2023 Q3	$3.09M	Hold	678,564	–	–	0.17%	26
2023 Q2	$4.78M	Hold	678,564	–	–	0.26%	24
2023 Q1	$4.15M	Hold	678,564	–	–	0.2%	34
2022 Q4	$4.34M	Hold	678,564	–	–	0.23%	34
2022 Q3	$6.5M	Hold	678,564	–	–	0.45%	32
2022 Q2	$7.49M	Hold	678,564	–	–	0.47%	31
2022 Q1	$11.3M	Hold	678,564	–	–	0.49%	25
2021 Q4	$13M	Hold	678,564	–	–	0.44%	25
2021 Q3	$16.7M	Hold	678,564	–	–	1.24%	11
2021 Q2	$17.7M	Buy	678,564 +89,048	+15%	+$2.31M	1.17%	10
2021 Q1	$18.7M	Buy	589,516 +68,396	+13%	+$2.84M	1.3%	9
2020 Q4	$24.2M	Sell	521,120 -51,851	-9%	-$2.06M	1.34%	10
2020 Q3	$18.9M	Sell	572,971 -71,757	-11%	-$2.2M	2.3%	12
2020 Q2	$17.7M	Hold	644,728	–	–	3.01%	12
2020 Q1	$19.3M	Sell	644,728 -376,633	-37%	-$9.98M	4.5%	8
2019 Q4	$28.3M	Hold	1,021,361	–	–	5.5%	3
2019 Q3	$18.6M	Hold	1,021,361	–	–	3.82%	6
2019 Q2	$23.9M	Hold	1,021,361	–	–	5.06%	5
2019 Q1	$9.24M	Hold	1,021,361	–	–	2.33%	13
2018 Q4	$8.7M	Buy	1,021,361 +200,000	+24%	+$1.93M	2.84%	13
2018 Q3	$8.75M	Hold	821,361	–	–	2.26%	16
2018 Q2	$10.5M	Sell	821,361 -590,334	-42%	-$8.63M	3.02%	10
2018 Q1	$22.5M	Buy	1,411,695 +287,400	+26%	+$4.35M	2.36%	11
2017 Q4	$8.62M	Buy	1,124,295 +463,486	+70%	+$3.72M	0.49%	28
2017 Q3	$5.02M	Hold	660,809	–	–	0.19%	46
2017 Q2	$4.69M	Sell	660,809 -724,500	-52%	-$4.61M	0.13%	51
2017 Q1	$10M	Sell	1,385,309 -113,500	-8%	-$832K	0.31%	42
2016 Q4	$10.3M	Sell	1,498,809 -252,700	-14%	-$1.74M	0.31%	41
2016 Q3	$14.3M	Buy	1,751,509 +153,200	+10%	+$1.3M	0.54%	33
2016 Q2	$12.9M	Hold	1,598,309	–	–	0.89%	34
2016 Q1	$8.12M	Buy	1,598,309 +164,609	+11%	+$901K	0.5%	56
2015 Q4	$11.1M	Hold	1,433,700	–	–	0.62%	42
2015 Q3	$8.26M	Hold	1,433,700	–	–	0.28%	54
2015 Q2	$13.1M	Buy	1,433,700 +108,700	+8%	+$1.21M	0.2%	50
2015 Q1	$16M	Buy	+1,325,000	New	+$14.9M	0.89%	29

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

QVT Financial's IOVA Position: Q2 2026 in Review

QVT Financial held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 678,564 shares worth $2.82M. The position accounts for 0.17% of the portfolio, ranked #41.

QVT Financial first reported a position in IOVA in Q1 2015 and has held it in 46 quarters since. The position peaked at $28.3M in Q4 2019. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

QVT Financial held 678,564 shares of Iovance Biotherapeutics worth $2.82M as of Q2 2026.
QVT Financial left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up 0.17% of QVT Financial's portfolio in Q2 2026, its #41 holding.
QVT Financial first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 46 quarters since.
QVT Financial's Iovance Biotherapeutics position peaked at $28.3M in Q4 2019.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on QVT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.